Evidence map›Paper›PMID 25338703›Full record

ArticleChemMedChem2015

O-(triazolyl)methyl carbamates as a novel and potent class of fatty acid amide hydrolase (FAAH) inhibitors.

Giampiero Colombano, Clara Albani, Giuliana Ottonello, Alison Ribeiro, Rita Scarpelli, Glauco Tarozzo, Jennifer Daglian, Kwang-Mook Jung, Daniele Piomelli, Tiziano Bandiera

Open access · greenAbstract read
In one paragraph

Article in ChemMedChem, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Giampiero ColombanoDrug Discovery & Development, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova (Italy); The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey SM2 5NG (UK). giampiero.colombano@iit.it, giampiero.colombano@icr.ac.uk.
Clara Albani
Giuliana Ottonello
Alison Ribeiro
Rita Scarpelli
Glauco Tarozzo
Jennifer Daglian
Kwang-Mook Jung
Daniele Piomelli
Tiziano Bandiera
Italian Institute of Technology · ITUniversity of California, Irvine · US

Funding

Characterization of Anandamide Transport in BrainR01DA012413 · NIDA · UNIVERSITY OF CALIFORNIA-IRVINE · PI PIOMELLI, DANIELE · 1998 to 2016
$4.7M
Optimization and preclinical development of FAAH inhibitors for smoking cessationDP1DA031387 · NIDA · UNIVERSITY OF CALIFORNIA-IRVINE · PI PIOMELLI, DANIELE · 2010 to 2014
$3.7M
NIDA NIH HHS DP1 DA031387NIDA NIH HHS DP1DA031387NIDA NIH HHS R01 DA012413NIDA NIH HHS R01-DA-012413
6 · The paper itself

Abstract

Inhibition of fatty acid amide hydrolase (FAAH) activity is under investigation as a valuable strategy for the treatment of several disorders, including pain and drug addiction. A number of potent FAAH inhibitors belonging to different chemical classes have been disclosed to date; O-aryl carbamates are one of the most representative families. In the search for novel FAAH inhibitors, a series of O-(1,2,3-triazol-4-yl)methyl carbamate derivatives were designed and synthesized exploiting a copper- catalyzed [3+2] cycloaddition reaction between azides and alkynes (click chemistry). Exploration of the structure-activity relationships within this new class of compounds identified potent inhibitors of both rat and human FAAH with IC50 values in the single-digit nanomolar range. In addition, these derivatives showed improved stability in rat plasma and kinetic solubility in buffer with respect to the lead compound. Based on the results of the study, the novel analogues identified can be considered to be promising starting point for the development of new FAAH inhibitors with improved drug-like properties.

Indexed as

AmidohydrolasesAnimalsCarbamatesCatalysisClick ChemistryCopperCycloaddition ReactionEnzyme InhibitorsFatty Acid Amide HydrolasesHalf-LifeHEK293 CellsHumansKineticsMaleMiceMicrosomes, LiverAmidohydrolasesCarbamatesCopperEnzyme InhibitorsFatty Acid Amide Hydrolasesmethyl carbamateRecombinant Proteinsclick chemistryfatty acid amide hydrolase (FAAH)inhibitorsO-(triazolyl)methyl carbamatesstructure-activity relationships

Identifiers

PMID25338703
PMCPMC4384654
OpenAlexW1974678631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.